Alembic Pharmaceuticals has filed an intimation with stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, notifying shareholders of an upcoming transfer of shares to the Investor Education and Protection Fund (IEPF). A copy of the notice was published in the Indian Express (English edition) and Financial Express (Gujarati edition) on 5th May, 2026, and was enclosed with the exchange communication signed by Company Secretary Manisha Saraf.

Background and Regulatory Basis

Pursuant to Section 124(6) of the Companies Act, 2013, and the Investor Education and Protection Fund Authority (Accounting, Auditing, Transfer and Refund) Rules, 2016, shares on which dividends have not been encashed or claimed for seven consecutive years or more are liable to be transferred to the IEPF — a fund constituted by the Government of India under Section 125 of the Companies Act, 2013. The shareholder notice was dated 2nd May, 2026, and dispatched by speed post. The company has individually communicated with all concerned shareholders at their registered addresses, and has uploaded details including names and Folio Number / DP ID Client ID on its website at https://alembicpharmaceuticals.com/iepf .

Dividends Covered Under the Notice

The company has identified shareholders who have not encashed dividend warrants for seven or more consecutive years, commencing from the unpaid dividend for the financial year 2018-2019. The following financial years are covered under this notice:

The company has noted that unclaimed dividends for periods prior to those listed above have already been transferred to the IEPF, as required under Section 124(5) of the Companies Act, 2013. Details of unclaimed dividends are available at https://alembicpharmaceuticals.com/unpaid-unclaimed-dividend .

Deadline and Reclaim Process

Shareholders have been requested to claim their unpaid dividends on or before 10th August, 2026, failing which the shares referenced in the notice will be transferred to the IEPF. Shareholders holding shares in physical form should note that upon transfer, original share certificates will stand automatically cancelled and deemed non-negotiable. For shareholders holding shares in demat form, the company will inform the concerned depository via corporate action for the transfer. Shareholders whose shares and corresponding dividends have been or will be transferred to the IEPF Authority's account may reclaim them by filing web form No. IEPF-5 with the IEPF Authority.

For claims or further information, shareholders may contact the company's Registrar and Share Transfer Agent:

KYC Compliance for Physical Shareholders

Shareholders holding shares in physical form who have not yet registered their KYC details — including PAN, address with PIN code, email ID, mobile number, bank account details, specimen signature, and nomination — are advised to submit the relevant forms. The applicable forms include ISR-1, ISR-2, ISR-3, SH-13, and SH-14, available on the company's website at https://alembicpharmaceuticals.com/investor-related-forms/ and on the RTA's website at https://in.mpms.mufg.com/ . The intimation was signed by Manisha Saraf, Company Secretary & Compliance Officer, on behalf of Alembic Pharmaceuticals, with the registered office located at Alembic Road, Vadodara – 390 003, Gujarat.

Alembic Pharmaceuticals Limited has notified the stock exchanges regarding the resignation of Mr. Goldee Pardesi from the position of Associate Vice President - Sales & Marketing. The resignation became effective from 4th May 2026, at the close of business hours, as per the intimation submitted to BSE Limited and National Stock Exchange of India Ltd.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has attached the required details as per the Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026.

Resignation Details

The following table outlines the key particulars of the change in senior management personnel:

The resignation intimation was signed by Manisha Saraf, Company Secretary of alembic pharmaceuticals , on 4th May 2026. The company's registered office is located at Alembic Road, Vadodara - 390 003.

The resignation follows an email communication from Mr. Pardesi dated 3rd February 2026, wherein he formally tendered his resignation to pursue new opportunities aligned with his professional and personal goals. He expressed gratitude for the support and opportunities provided during his tenure at the company.